Scientific Reports (Feb 2018)

Inhibitory modulation of cytochrome c oxidase activity with specific near-infrared light wavelengths attenuates brain ischemia/reperfusion injury

  • Thomas H. Sanderson,
  • Joseph M. Wider,
  • Icksoo Lee,
  • Christian A. Reynolds,
  • Jenney Liu,
  • Bradley Lepore,
  • Reneé Tousignant,
  • Melissa J. Bukowski,
  • Hollie Johnston,
  • Alemu Fite,
  • Sarita Raghunayakula,
  • John Kamholz,
  • Lawrence I. Grossman,
  • Karin Przyklenk,
  • Maik Hüttemann

DOI
https://doi.org/10.1038/s41598-018-21869-x
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 12

Abstract

Read online

Abstract The interaction of light with biological tissue has been successfully utilized for multiple therapeutic purposes. Previous studies have suggested that near infrared light (NIR) enhances the activity of mitochondria by increasing cytochrome c oxidase (COX) activity, which we confirmed for 810 nm NIR. In contrast, scanning the NIR spectrum between 700 nm and 1000 nm revealed two NIR wavelengths (750 nm and 950 nm) that reduced the activity of isolated COX. COX-inhibitory wavelengths reduced mitochondrial respiration, reduced the mitochondrial membrane potential (ΔΨm), attenuated mitochondrial superoxide production, and attenuated neuronal death following oxygen glucose deprivation, whereas NIR that activates COX provided no benefit. We evaluated COX-inhibitory NIR as a potential therapy for cerebral reperfusion injury using a rat model of global brain ischemia. Untreated animals demonstrated an 86% loss of neurons in the CA1 hippocampus post-reperfusion whereas inhibitory NIR groups were robustly protected, with neuronal loss ranging from 11% to 35%. Moreover, neurologic function, assessed by radial arm maze performance, was preserved at control levels in rats treated with a combination of both COX-inhibitory NIR wavelengths. Taken together, our data suggest that COX-inhibitory NIR may be a viable non-pharmacologic and noninvasive therapy for the treatment of cerebral reperfusion injury.